News tagged with erlotinib

Related topics: lung cancer

Tumors with ALK rearrangements can harbor more mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

Apr 22, 2013
popularity 3 / 5 (2) | comments 0

The right combination: Overcoming drug resistance in cancer

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...

Jun 01, 2012
popularity 5 / 5 (1) | comments 0

New treatment holds promise for resistant lung cancer

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...

Apr 09, 2013
popularity 5 / 5 (1) | comments 0

Erlotinib

Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.

This text uses material from Wikipedia licensed under CC BY-SA